RT Journal Article
T1 Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
A1 Salvador-Martín, Sara
A1 Raposo-Gutiérrez, Irene
A1 Navas-López, Víctor Manuel
A1 Gallego-Fernández, Carmen
A1 Moreno-Álvarez, Ana
A1 Solar-Boga, Alfonso
A1 Muñoz-Codoceo, Rosana
A1 Magallares, Lorena
A1 Martínez-Ojinaga, Eva
A1 Fobelo, María J.
A1 Millán-Jiménez, Antonio
A1 Rodriguez-Martinez, Alejandro
A1 Vayo, Concepción A.
A1 Sánchez, Cesar
A1 Tolin, Mar
A1 Bossacoma, Ferrán
A1 Pujol-Muncunill, Gemma
A1 González de Caldas, Rafael
A1 Loverdos, Inés
A1 Blanca-García, José A.
A1 Segarra, Oscar
A1 Eizaguirre, Francisco J.
A1 García-Romero, Ruth
A1 Merino-Bohórquez, Vicente
A1 Sanjurjo-Sáez, María
A1 López-Fernández, Luis A.
K1 Biomarker
K1 Gene expression
K1 Infliximab
K1 Adalimumab
K1 Ulcerative colitis
K1 Crohn’s disease
K1 Biomarcadores
K1 Expresión génica
K1 Colitis ulcerosa
K1 Enfermedad de Crohn
AB Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2-∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
PB MDPI
YR 2020
FD 2020-05-09
LK http://hdl.handle.net/10668/3700
UL http://hdl.handle.net/10668/3700
LA en
NO Salvador-Martín S, Raposo-Gutiérrez I, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, Solar-Boga A, et al. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Int J Mol Sci. 2020 May 9;21(9):3364
DS RISalud
RD Apr 4, 2025